Cargando…
Differentiating pulmonary hypertension associated with protein kinase inhibitors
Protein kinase inhibitors (PKIs) have been implicated in pulmonary vascular toxicities including risk factors for at least three of the five World Health Organization groups of pulmonary hypertension (PH). These toxicities include direct drug‐induced pulmonary arterial hypertension, an increase in c...
Autores principales: | Jacobs, Joshua A., Jahangir, Eiman, Ryan, John J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248793/ https://www.ncbi.nlm.nih.gov/pubmed/35795494 http://dx.doi.org/10.1002/pul2.12075 |
Ejemplares similares
-
Pulmonary hypertension with dasatinib and other tyrosine kinase
inhibitors
por: El-Dabh, Ashraf, et al.
Publicado: (2019) -
Tyrosine Kinase Inhibitors in Pulmonary Vascular Disease
por: Ryan, John J.
Publicado: (2016) -
Differential effects of integrin-linked kinase inhibitor Cpd22 on severe pulmonary hypertension in male and female rats
por: Shen, Yuanjun, et al.
Publicado: (2020) -
Management of Pulmonary Arterial Hypertension
por: Mayeux, Jennalyn D., et al.
Publicado: (2020) -
Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment
por: Pitsiou, Georgia, et al.
Publicado: (2014)